Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Bottini, Gabriella; | Berlingeri, Manuela | Basilico, Stefania | Passoni, Serena | Danelli, Laura | Colombo, Nadia | Sberna, Maurizio | Franceschi, Massimo | Sterzi, Roberto | Paulesu, Eraldo;
Affiliations: Psychology Department, University of Pavia, Pavia, Italy | Center of Cognitive Neuropsychology, Niguarda Cà Granda Hospital, Milan, Italy | Psychology Department, University of Milano-Bicocca, Milan, Italy | Neuroradiology Department, Niguarda Cà Granda Hospital, Milan, Italy | Neurology Unit, Clinic "Santa Maria", Castellanza, Italy | Neurology Department, Niguarda Cà Granda Hospital, Milan, Italy | IRCCS Galeazzi, Milan, Italy
Note: [] Corresponding author: Eraldo Paulesu, Dipartimento di Psicologia, Università degli Studi di Milano-Bicocca, Piazza dell'Ateneo Nuovo 1, 20122 Milano, Italia. Tel.: +39 2 64483748; Fax: +39 2 64483706; E-mail: eraldo.paulesu@unimib.it
Abstract: We explored the neuropsychological and neuromorphometrical differences between probable Alzheimer's disease patients showing a good or a bad response to nine months treatment with donepezil. Before treatment, the neuropsychological profile of the two patient groups was perfectly matched. By the ninth month after treatment, the BAD-responders showed a decline of the MMSE score together with a progressive impairment of executive functions. A voxel-based morphometry investigation (VBM), at the time of the second neuropsychological assessment, showed that the BAD-responders had larger grey and white matter atrophies involving the substantia innominata of Meynert bilaterally, the ventral part of caudate nuclei and the left uncinate fasciculus, brain areas belonging to the cholinergic pathways. A more widespread degeneration of the central cholinergic pathways may explain the lack of donepezil efficacy in those patients not responding to a treatment that operates on the grounds that some degree of endogeneous release of acetylcholine is still available.
Keywords: Acetilcholinesterase inhibitors, Alzheimer's disease, donepezil, MRI, voxel-based morphometry
DOI: 10.3233/BEN-2011-0359
Journal: Behavioural Neurology, vol. 25, no. 2, pp. 61-72, 2012
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl